trimethoprim-sulfamethoxazole
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04230746 | Oct 2023 → Feb 2025 | bacterial infectious disease, bacteriuria, microtia, urinary tract infection | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 11 trial | ||||||
| Phase 1 | NCT02475876 | Nov 2015 → Aug 2018 | gram-positive bacterial infections | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05418777 | Sep → Dec 2022 | chronic obstructive pulmonary disease | Corewell Health East | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03919435 | Mar 2019 → Dec 2027 expected | granulomatosis with polyangiitis | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01101412 | — | cancer of unknown primary site, infectious disease, leukemia, lymphoproliferative syndrome +3 | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07451171 | Apr → Aug 2026 overdue | small intestinal bacterial overgrowth | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT07224997 | Dec 2025 → Jul 2027 expected | acute kidney injury | Hospital Civil de Guadalajara | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00730028 | Apr 2009 → Feb 2015 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07202091 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05678621 | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00729937 | Apr 2009 → May 2013 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT06336824 | Jun 2024 → May 2025 overdue | staphylococcus aureus infection | Clinical Research Centre, Malaysia | Recruiting | No outcome recorded |
| Phase 3 | NCT01792804 | Dec 2013 → Mar 2020 | staphylococcus aureus infection | Heinrich-Heine University, Duesseldorf | Completed | Met primary |
| Phase 3 | NCT00527800 | Aug 2007 → Mar 2013 | HIV infectious disease, malaria | University of California, San Francisco | Completed | Met primary |
| Phase 48 trials · 2 met primary | ||||||
| Phase 4 | NCT07106125 | Oct 2028 → Dec 2031 expected | urinary tract infection | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06982105 | May 2025 → Jun 2027 expected | bacterial arthritis, cervical lymphadenitis, mastoiditis, methicillin-resistant staphylococcus aureus infectious disease +3 | Indiana University | Recruiting | No outcome recorded |
| Phase 4 | NCT05438082 | Oct 2023 → Oct 2024 | urinary tract infection | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT05199324 | Jun 2022 → May 2026 overdue | gram-negative bacterial infections | Tan Tock Seng Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04502095 | Sep 2020 → Mar 2025 | urinary bladder carcinoma, urinary tract infection | Roswell Park Cancer Institute | Completed | Met primary |
| Phase 4 | NCT00711854 | Jan 2009 → Dec 2013 | methicillin-resistant staphylococcus aureus infectious disease | University Hospital, Geneva | Completed | Met primary |
| Phase 4 | NCT00613769 | Sep 2007 → Dec 2011 | — | Halmstad County Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00126698 | Jan 2005 → Apr 2007 | bacteriuria, urinary tract infection | St. Antonius Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials · 2 missed | ||||||
| — | NCT02096159 | Mar 2014 → Dec 2018 overdue | hypospadias | Ann & Robert H Lurie Children's Hospital of Chicago | Active not recruiting | Missed primary |
| — | NCT01232231 | Jul 2010 → Apr 2012 | methicillin-resistant staphylococcus aureus infectious disease | Joseph Kim | Completed | No outcome recorded |
| — | NCT02024867 | Feb 2010 → Jan 2012 | abscess, skin disease caused by bacterial infection | Lucy Holmes, MD | Completed | Missed primary |
| — | NCT00867789 | Mar 2009 → Oct 2012 | abscess | Children's Mercy Hospital Kansas City | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00676130 | May 2007 → May 2012 | cellulitis | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00428818 | Aug 2005 → Jul 2006 | infectious disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Comparator or background therapy26 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03178149 Background | Jul 2018 → Dec 2027 expected | age-related macular degeneration | Astellas Institute for Regenerative Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT00004216 Background | Aug 1999 → Jan 2008 | cancer of unknown primary site | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00061945 Background | Jun 2003 → Dec 2007 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00869518 Comparator | Jul 2009 → Dec 2010 | HIV infectious disease, staphylococcus aureus infection | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00391651 Comparator | Jan 2002 → Jul 2005 | urinary tract infection | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00002571 Background | Jun 1994 → Nov 2003 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00002524 Background | Jun 1993 → Oct 2005 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT04851015 Comparator | Nov 2025 → Sep 2030 expected | pneumocystosis | Todd C. Lee MD MPH FIDSA | Recruiting | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04368559 Comparator | May 2020 → Jan 2026 | aspergillosis, candidemia, pneumocystosis | Mundipharma Research Limited | Completed | Met primary |
| Phase 3 | NCT01449877 Comparator | Oct 2011 → Nov 2013 | ocular toxoplasmosis | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 3 | NCT00752375 Comparator | Feb 2009 → Dec 2014 | pyelonephritis | University of Alberta | Withdrawn | No outcome recorded |
| Phase 3 | NCT00973765 Comparator | Nov 2007 → Aug 2009 | abscess | 59th Medical Wing | Completed | No outcome recorded |
| Phase 3 | NCT00302341 Comparator | May 2006 → Dec 2008 | HIV infectious disease, pneumocystosis | Immtech Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00791505 Comparator | Jul 2002 → Jun 2005 | chronic obstructive pulmonary disease, infectious disease with sepsis | University of Monastir | Completed | No outcome recorded |
| Phase 4 | NCT07236944 Comparator | Dec 2025 → Mar 2029 expected | bacterial urinary tract infection | Uppsala University | Recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT02357758 Comparator | Sep 2012 → Jan 2016 | urinary tract infection | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 4 | NCT01659866 Comparator | Aug 2012 → Aug 2015 | infectious disease | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT02123628 Comparator | Jun 2007 → Jun 2010 | diabetes mellitus | Tourcoing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00679302 Comparator | Jul 2006 → Feb 2008 | skin infection | St. Louis University | Completed | No outcome recorded |
| — | NCT06207786 Background | Sep 2024 → May 2029 | epidermal appendage tumor, skin cancer | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT06080698 Comparator | Feb 2024 → May 2027 expected | gram-negative bacterial infections | Johns Hopkins University | Recruiting | No outcome recorded |
| — | NCT01650558 Comparator | Nov 2012 → Jul 2018 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01049438 Background | Aug 2006 → Sep 2009 | methicillin-resistant staphylococcus aureus infectious disease | Natividad Medical Center | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 55 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trimethoprim-sulfamethoxazole | “338 women aged 18 to 45 years with acute uncomplicated cystitis were randomized to open-label treatment with either trimethoprim-sulfamethoxazole, 1 double-strength tablet...” PMID 17998493 ↗ Nov 200756“The aim of this study is to add trimethoprim-sulfamethoxazole (TMP-SMX) to standard of care treatment of AECOPD in patients who are colonized with PJ will improve the clinical...” NCT05418777 ↗ “rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days” NCT00869518 ↗ “We evaluate whether trimethoprim-sulfamethoxazole reduces the rate of treatment failures during the 7 days after incision and drainage” PMID 20346539 ↗ Mar 2010 “* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.” NCT05074147 ↗ “one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension.” NCT05438082 ↗ “We then assessed the response of uropathogenic E. faecalis to nitrofurantoin and trimethoprim-sulfamethoxazole.” PMID 30132694 ↗ Aug 2018 “daily trimethoprim-sulfamethoxazole (TS) prophylaxis reduced morbidity and mortality among HIV-infected adults” PMID 27431995 ↗ Jul 2016 “Includes antibiotics such as amoxicillin, cephalexin, ciprofloxacin, and trimethoprim-sulfamethoxazole.” NCT06080698 ↗ “trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days” NCT01232231 ↗ “trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections” NCT06982105 ↗ |
| Known as | Bactrim F | “Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F” NCT07224997 ↗ |
| Known as | co-trimoxazole | “Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg.” NCT05678621 ↗1“Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F” NCT07224997 ↗ |
| Known as | Sulfamethoxazole 800mg + Trimethoprim 160mg = Bactrim F. | “Sulfamethoxazole 800mg + Trimethoprim 160mg = Bactrim F.” NCT01449877 ↗ |
| Known as | sulfamethoxazole-trimethoprim | “Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F” NCT07224997 ↗ |
| Known as | TMP/SMX | “The aim of this study is to add trimethoprim-sulfamethoxazole (TMP-SMX) to standard of care treatment of AECOPD in patients who are colonized with PJ will improve the clinical...” NCT05418777 ↗11“Low piperaquine concentrations were associated with an increased risk of recurrent malaria for up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole...” PMID 23447696 ↗ Feb 2013 “The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events” NCT04851015 ↗ “Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX” NCT00730028 ↗ “seven days of rifabutin plus trimethoprim-sulfamethoxazole (TMP-SMX) or TMP-SMX alone” NCT00869518 ↗ “trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections” NCT06982105 ↗ “Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours” NCT07224997 ↗ “common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX)” NCT07106125 ↗ “Drug: trimethoprim-sulfamethoxazole (TMP-SMX)” NCT00711854 ↗ “Trimethoprim/Sulfamethoxazole (TMP/SMX)” NCT00729937 ↗ “Trimethoprim-sulfamethoxazole (TMP/SMX)” NCT07451171 ↗ |
| Route | Oral | “1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles” NCT00002571 ↗ |